Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies

MT Newswires Live01-14

Mesoblast (ASX:MSB) is likely to complete more patient therapies with Ryoncil than expected in fiscal 2026, according to a Tuesday Jefferies note.

It is now expected that 85 patients, up from 78 previously, will complete therapy in fiscal 2026, representing about 23% of the total US patients treated per year, the investment firm said.

The company on Jan. 9 said it earned gross revenue of $35.1 million from the sale of its mesenchymal stromal cell product Ryoncil for the quarter ended Dec. 31, 2025, up 60% from the quarter ended Sept. 30, 2025.

Jefferies said the gross revenue equates to 181 paid Ryoncil infusions, of which 28 were completed in the second quarter of fiscal 2026, with around 17 patients having completed treatment.

Jefferies kept a buy rating on Mesoblast and raised its price target to AU$3.50 from AU$3.30.

The company's shares fell around 2% in recent Wednesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603652526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603652526","market":"sh","top_or_hot":-1,"title":"Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) is likely to complete more patient therapies with Ryoncil than expected in fiscal 2026, according to a Tuesday Jefferies note.</p><p>It is now expected that 85 patients, up from 78 previously, will complete therapy in fiscal 2026, representing about 23% of the total US patients treated per year, the investment firm said.</p><p>The company on Jan. 9 said it earned gross revenue of $35.1 million from the sale of its mesenchymal stromal cell product Ryoncil for the quarter ended Dec. 31, 2025, up 60% from the quarter ended Sept. 30, 2025.</p><p>Jefferies said the gross revenue equates to 181 paid Ryoncil infusions, of which 28 were completed in the second quarter of fiscal 2026, with around 17 patients having completed treatment.</p><p>Jefferies kept a buy rating on Mesoblast and raised its price target to AU$3.50 from AU$3.30.</p><p>The company's shares fell around 2% in recent Wednesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-14 09:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) is likely to complete more patient therapies with Ryoncil than expected in fiscal 2026, according to a Tuesday Jefferies note.</p><p>It is now expected that 85 patients, up from 78 previously, will complete therapy in fiscal 2026, representing about 23% of the total US patients treated per year, the investment firm said.</p><p>The company on Jan. 9 said it earned gross revenue of $35.1 million from the sale of its mesenchymal stromal cell product Ryoncil for the quarter ended Dec. 31, 2025, up 60% from the quarter ended Sept. 30, 2025.</p><p>Jefferies said the gross revenue equates to 181 paid Ryoncil infusions, of which 28 were completed in the second quarter of fiscal 2026, with around 17 patients having completed treatment.</p><p>Jefferies kept a buy rating on Mesoblast and raised its price target to AU$3.50 from AU$3.30.</p><p>The company's shares fell around 2% in recent Wednesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603652526","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603652526","pubTimestamp":1768353853,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast (ASX:MSB) is likely to complete more patient therapies with Ryoncil than expected in fiscal 2026, according to a Tuesday Jefferies note.It is now expected that 85 patients, up from 78 previo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","MSB.AU":"MESOBLAST LTD","BK7501":"新冠治疗股","MESO":"Mesoblast Limited","BK4139":"生物科技"},"translate_title":"Jefferies表示，Mesoblast在2026财年完成的Ryoncil疗法可能会超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5,"MSB.AU":1},"content_text":"Mesoblast (ASX:MSB) is likely to complete more patient therapies with Ryoncil than expected in fiscal 2026, according to a Tuesday Jefferies note.It is now expected that 85 patients, up from 78 previously, will complete therapy in fiscal 2026, representing about 23% of the total US patients treated per year, the investment firm said.The company on Jan. 9 said it earned gross revenue of $35.1 million from the sale of its mesenchymal stromal cell product Ryoncil for the quarter ended Dec. 31, 2025, up 60% from the quarter ended Sept. 30, 2025.Jefferies said the gross revenue equates to 181 paid Ryoncil infusions, of which 28 were completed in the second quarter of fiscal 2026, with around 17 patients having completed treatment.Jefferies kept a buy rating on Mesoblast and raised its price target to AU$3.50 from AU$3.30.The company's shares fell around 2% in recent Wednesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603652526","isCrawlerRequest":true}